U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H48N6O8
Molecular Weight 560.685
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEFEROXAMINE

SMILES

CC(=O)N(CCCCCN=C(CCC(=O)N(CCCCCN=C(CCC(=O)N(CCCCCN)O)O)O)O)O

InChI

InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N
InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)

HIDE SMILES / InChI

Molecular Formula C25H48N6O8
Molecular Weight 560.685
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Deferoxamine (brand name Desferal) an iron chelator, is a drug for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Deferoxamine chelates iron by forming a stable complex that prevents the iron entering into further chemical reactions. However, drug may cause hypersensitivity reactions, systemic allergic reactions, and cardiovascular, hematologic and neurological adverse reactions. Serious adverse reactions include significant hypotension and marked body weight loss. Principally plasma enzymes metabolize deferoxamine, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rats. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2363058
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
DESFERAL

Approved Use

Deferoxamine Mesylate for Injection, USP is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder.

Launch Date

-5.5296E10
Palliative
DESFERAL

Approved Use

Deferoxamine Mesylate for Injection, USP is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder.

Launch Date

-5.5296E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.4 μM
10 mg/kg 1 times / day other, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.9 μM
100 mg/kg 1 times / day other, intravenous
dose: 100 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15.7 μM
10 mg/kg single, intramuscular
dose: 10 mg/kg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.5 μM
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.7 μM
100 mg/kg 1 times / day other, intravenous
dose: 100 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.1 μM
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7 μM
10 mg/kg single, intramuscular
dose: 10 mg/kg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
10.1 μM
40 mg/kg single, subcutaneous
dose: 40 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
354 μM × h
10 mg/kg 1 times / day other, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.05 h
10 mg/kg 1 times / day other, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.59 h
40 mg/kg single, subcutaneous
dose: 40 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
DEFEROXAMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
700 mg/kg 1 times / day single, intravenous
Studied dose
Dose: 700 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 700 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: sickle cell-beta thalassemia
Age Group: 17 years
Sex: M
Population Size: 1
Sources:
Other AEs: Renal failure...
Other AEs:
Renal failure
Sources:
135 mg/kg 1 times / day multiple, intravenous (mean)
Studied dose
Dose: 135 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 135 mg/kg, 1 times / day
Sources:
unhealthy, meadian age 12 years
n = 10
Health Status: unhealthy
Condition: recurrent neuroblastoma
Age Group: meadian age 12 years
Sex: M+F
Population Size: 10
Sources:
Disc. AE: Visual disturbances...
AEs leading to
discontinuation/dose reduction:
Visual disturbances
Sources:
240 mg/kg 1 times / day multiple, intravenous
Studied dose
Dose: 240 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 240 mg/kg, 1 times / day
Sources:
unhealthy, meadian age 12 years
n = 10
Health Status: unhealthy
Condition: recurrent neuroblastoma
Age Group: meadian age 12 years
Sex: M+F
Population Size: 10
Sources:
DLT: Lethargy, Dizziness...
Dose limiting toxicities:
Lethargy
Dizziness
Blurred vision
Leg cramps
Sources:
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
DLT: Aspiration pneumonia...
Other AEs: Hyperglycaemia, Vomiting...
Dose limiting toxicities:
Aspiration pneumonia (33.3%)
Other AEs:
Hyperglycaemia (grade 1, 16.7%)
Vomiting (grade 1, 16.7%)
Fatigue (grade 1, 16.7%)
Infection (grade 1, 16.7%)
Urinary tract infection (grade 1, 33.3%)
Blood pressure decreased (grade 1, 16.7%)
Hyponatraemia (grade 1, 16.7%)
Agitation (grade 1, 16.7%)
Convulsion (grade 1, 16.7%)
Headache (grade 1, 16.7%)
Lethargy (grade 1, 16.7%)
Delirium (grade 1, 16.7%)
Depression (grade 1, 16.7%)
Respiratory failure (grade 1, 33.3%)
Rash (grade 1, 16.7%)
Skin irritation (grade 1, 16.7%)
Deep vein thrombosis (grade 1, 16.7%)
Hypotension (grade 1, 16.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Renal failure
700 mg/kg 1 times / day single, intravenous
Studied dose
Dose: 700 mg/kg, 1 times / day
Route: intravenous
Route: single
Dose: 700 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Condition: sickle cell-beta thalassemia
Age Group: 17 years
Sex: M
Population Size: 1
Sources:
Visual disturbances Disc. AE
135 mg/kg 1 times / day multiple, intravenous (mean)
Studied dose
Dose: 135 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 135 mg/kg, 1 times / day
Sources:
unhealthy, meadian age 12 years
n = 10
Health Status: unhealthy
Condition: recurrent neuroblastoma
Age Group: meadian age 12 years
Sex: M+F
Population Size: 10
Sources:
Blurred vision DLT
240 mg/kg 1 times / day multiple, intravenous
Studied dose
Dose: 240 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 240 mg/kg, 1 times / day
Sources:
unhealthy, meadian age 12 years
n = 10
Health Status: unhealthy
Condition: recurrent neuroblastoma
Age Group: meadian age 12 years
Sex: M+F
Population Size: 10
Sources:
Dizziness DLT
240 mg/kg 1 times / day multiple, intravenous
Studied dose
Dose: 240 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 240 mg/kg, 1 times / day
Sources:
unhealthy, meadian age 12 years
n = 10
Health Status: unhealthy
Condition: recurrent neuroblastoma
Age Group: meadian age 12 years
Sex: M+F
Population Size: 10
Sources:
Leg cramps DLT
240 mg/kg 1 times / day multiple, intravenous
Studied dose
Dose: 240 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 240 mg/kg, 1 times / day
Sources:
unhealthy, meadian age 12 years
n = 10
Health Status: unhealthy
Condition: recurrent neuroblastoma
Age Group: meadian age 12 years
Sex: M+F
Population Size: 10
Sources:
Lethargy DLT
240 mg/kg 1 times / day multiple, intravenous
Studied dose
Dose: 240 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 240 mg/kg, 1 times / day
Sources:
unhealthy, meadian age 12 years
n = 10
Health Status: unhealthy
Condition: recurrent neuroblastoma
Age Group: meadian age 12 years
Sex: M+F
Population Size: 10
Sources:
Aspiration pneumonia 33.3%
DLT
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Agitation grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Blood pressure decreased grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Convulsion grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Deep vein thrombosis grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Delirium grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Depression grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Fatigue grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Headache grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Hyperglycaemia grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Hyponatraemia grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Hypotension grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Infection grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Lethargy grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Rash grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Skin irritation grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Vomiting grade 1, 16.7%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Respiratory failure grade 1, 33.3%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Urinary tract infection grade 1, 33.3%
62 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 62 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 62 mg/kg, 1 times / day
Sources:
unhealthy, median age 70 years
n = 6
Health Status: unhealthy
Condition: intracerebral hemorrhage
Age Group: median age 70 years
Sex: M+F
Population Size: 6
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [Activation >10 uM]
no [Activation >10 uM]
no [Activation >10 uM]
no [Activation >10 uM]
no [Activation >10 uM]
yes
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparison of IY81149 with omeprazole in rat reflux oesophagitis.
2000 Oct-Dec
Electron paramagnetic resonance detection of free radicals in UV-irradiated human and mouse skin.
2001
Hypercalcemia and human nature.
2001 Apr
Persistence of delayed adrenarche in boys with thalassemia.
2001 Apr
Yersinia enterocolitica as a cause of intra-abdominal abscess: the role of iron.
2001 Apr
Relationship of fiber surface iron and active oxygen species to expression of procollagen, PDGF-A, and TGF-beta(1) in tracheal explants exposed to amosite asbestos.
2001 Apr
A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate.
2001 Apr
Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells.
2001 Apr 15
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
2001 Apr 20
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
2001 Apr 20
Klebsiella pneumoniae meningitis in thalassemia major patients.
2001 Apr-May
Lucigenin chemiluminescence in human seminal plasma.
2001 Feb
Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.
2001 Feb 1
Cellular sites of H2O2-induced damage and their protection by nitroxides.
2001 Feb 16
Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line.
2001 Feb 26
Iron-induced changes in nitric oxide and superoxide radical generation in rat liver after lindane or thyroid hormone treatment.
2001 Feb 28
Cytochrome b(5) plays a key role in human microsomal chromium(VI) reduction.
2001 Feb 28
Temporary treatment with sirolimus and low-trough cyclosporine prevents acute islet allograft rejection, and combination with starch-conjugated deferoxamine promotes islet engraftment in the preclinical pig model.
2001 Feb-Mar
The role of oxygen-derived free radicals in augmented relaxations to levcromakalim in the aorta from hypertensive rats.
2001 Jan
Oxidative insult in sheep red blood cells induced by T-butyl hydroperoxide: the roles of glutathione and glutathione peroxidase.
2001 Jan
Effects of hyperoxia and iron on iron regulatory protein-1 activity and the ferritin synthesis in mouse peritoneal macrophages.
2001 Jan 12
Interaction between iron(II) and hydroxamic acids: oxidation of iron(II) to iron(III) by desferrioxamine B under anaerobic conditions.
2001 Jan 15
Regulation of the 75-kDa subunit of mitochondrial complex I by iron.
2001 Jul 20
Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms.
2001 Jun 1
Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis.
2001 Jun 22
Vanadium-induced nuclear factor of activated T cells activation through hydrogen peroxide.
2001 Jun 22
Possible role of hydroxyl radicals in the oxidation of dichloroacetonitrile by Fenton-like reaction.
2001 Mar
Classification of Ralstonia pickettii biovar 3/'thomasii' strains (Pickett 1994) and of new isolates related to nosocomial recurrent meningitis as Ralstonia mannitolytica sp. nov.
2001 Mar
Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey.
2001 Mar
Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
2001 Mar
Hemoproteins affect H(2)O(2) removal from rat tissues.
2001 Mar
Role of the epithelium in opposing H(2)O(2)-induced modulation of acetylcholine-induced contractions in rabbit intrapulmonary bronchiole.
2001 Mar
Influence of iron restriction on Chlamydia pneumoniae and C. trachomatis.
2001 Mar
Mitochondrial involvement in cocaine-treated rat hepatocytes: effect of N-acetylcysteine and deferoxamine.
2001 Mar
IL-4 gene expression up-regulated by mercury in rat mast cells: a role of oxidant stress in IL-4 transcription.
2001 Mar
Enterobactin: the characteristic catecholate siderophore of Enterobacteriaceae is produced by Streptomyces species.(1).
2001 Mar 15
Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice.
2001 Mar 16
Atherosclerosis: defeat of the defense?
2001 Mar 16
Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue. Its potential role in alcohol-promoted mammary cancer.
2001 Mar 7
Evaluation of a new selective medium for methicillin-resistant Staphyloccocus aureus.
2001 May
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals.
2001 May
The controversial role of deferiprone in the treatment of thalassemia.
2001 May
Tc-99m MDP and Ga-67 citrate scintigraphic findings in sarcoidosis with osseous involvement.
2001 May
A case of malignant lymphoma with testis involvement detected by Ga-67 scan.
2001 May
Primary breast lymphoma detected with Tc-99m tetrofosmin scintigraphy.
2001 May
Cellular titration of apoptosis with steady state concentrations of H(2)O(2): submicromolar levels of H(2)O(2) induce apoptosis through Fenton chemistry independent of the cellular thiol state.
2001 May 1
DNA breakage induced by 1,2,4-benzenetriol: relative contributions of oxygen-derived active species and transition metal ions.
2001 May 1
Regulatory interactions between iron and nitric oxide metabolism for immune defense against Plasmodium falciparum infection.
2001 May 1
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus.
2001 May 15
Induction of oxidative stress by humic acid through increasing intracellular iron: a possible mechanism leading to atherothrombotic vascular disorder in blackfoot disease.
2001 May 18
Patents

Sample Use Guides

Acute Iron Intoxication: Intramuscular Administration: This route is preferred and should be used for ALL PATIENTS NOT IN SHOCK: A dose of 1000 mg should be administered initially. This may be followed by 500 mg every 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered every 4-12 hours. The total amount administered should not exceed 6000 mg in 24 hours Intravenous Administration: THIS ROUTE SHOULD BE USED ONLY FOR PATIENTS IN A STATE OF CARDIOVASCULAR COLLAPSE AND THEN ONLY BY SLOW INFUSION. THE RATE OF INFUSION SHOULD NOT EXCEED 15 MG/KG/HR FOR THE FIRST 1000 MG ADMINISTERED. SUBSEQUENT IV DOSING, IF NEEDED, MUST BE AT A SLOWER RATE, NOT TO EXCEED 125 MG/HR: An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours. The total amount administered should not exceed 6000 mg in 24 hours. CHRONIC IRON OVERLOAD: SUBCUTANEOUS ADMINISTRATION: A daily dose of 1000-2000 mg (20-40 mg/kg/day) should be administered over 8-24 hours, utilizing a small portable pump capable of providing continuous mini-infusion. The duration of infusion must be individualized. In some patients, as much iron will be excreted after a short infusion of 8-12 hours as with the same dose given over 24 hours. Intravenous Administration: The standard recommended method of Desferal administration is via slow subcutaneous infusion over 8 – 12 hours. In patients with intravenous access, the daily dose of Desferal can be administered intravenously. The standard dose is 20 – 40 mg/kg/day for children and 40–50 mg/kg/day over 8 – 12 hours in adults for 5 – 7 days per week. In children, average doses should not exceed 40 mg/kg/day until growth has ceased. In adults, average doses should not exceed 60 mg/kg/day. The intravenous infusion rate should not exceed 15 mg/kg/hour. Intramuscular Administration: A daily dose of 500-1000 mg may be administered intramuscularly. The total daily dose should not exceed 1000 mg.
Route of Administration: Other
In Vitro Use Guide
Curator's Comment:: It was investigated the effect of deferoxamine on mesenchymal stromal cells (MSCs). Ex vivo cultured stem cells derived from tumor and bone marrow compartment were exposed to Deferoxamine (DFO). It was revealed, that DFO had growth-arresting and apoptosis-inducing effect on tumor-associated MSCs (TAMSCs) and bone marrow MSCs (BMMSCs). DFO also influenced the expression pattern of adhesion molecule VCAM-1 on both TAMSCs and BMMSCs.
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:44:38 UTC 2021
Edited
by admin
on Fri Jun 25 21:44:38 UTC 2021
Record UNII
J06Y7MXW4D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEFEROXAMINE
HSDB   INN   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
DESFERRIOXAMINE B
Common Name English
DEFEROXAMINE [INN]
Common Name English
BUTANEDIAMIDE, N'-(5-((4-((5-(ACETYLHYDROXYAMINO)PENTYL)AMINO)-1,4-DIOXOBUTYL)HYDROXYAMINO)PENTYL)-N-(5-AMINOPENTYL)-N-HYDROXY-
Systematic Name English
N-(5-(3-((5-AMINOPENTYL)HYDROXYCARBAMOYL)PROPIONAMIDO)PENTYL)-3-((5-(N-HYDROXYACETAMIDO)PENTYL)CARBAMOYL)PROPIONOHYDROXAMIC ACID
Systematic Name English
DEFEROXAMINE [VANDF]
Common Name English
DEFEROXAMINE [HSDB]
Common Name English
DFO-B
Common Name English
DEFEROXAMINE [USAN]
Common Name English
DESFEROXAMINE B
Common Name English
DEFEROXAMINE [WHO-DD]
Common Name English
NSC-527604
Code English
DESFERRIOXAMINE
Common Name English
DEFEROXAMINE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QV03AC01
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
FDA ORPHAN DRUG 52290
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
FDA ORPHAN DRUG 633618
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
NDF-RT N0000175522
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
LIVERTOX 274
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
WHO-ATC V03AC01
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
NDF-RT N0000000144
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 10.3
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
NCI_THESAURUS C62357
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 4.2
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
Code System Code Type Description
PUBCHEM
2973
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
INN
1682
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
HSDB
3311
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
EPA CompTox
70-51-9
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
WIKIPEDIA
DEFEROXAMINE
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
CAS
70-51-9
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
NCI_THESAURUS
C416
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
MESH
D003676
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
EVMPD
SUB06942MIG
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
MERCK INDEX
M4133
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY Merck Index
FDA UNII
J06Y7MXW4D
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
DRUG BANK
DB00746
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-738-5
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
RXCUI
3131
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
792
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
ChEMBL
CHEMBL556
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
LACTMED
Deferoxamine
Created by admin on Fri Jun 25 21:44:38 UTC 2021 , Edited by admin on Fri Jun 25 21:44:38 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY